CTOs on the Move

APAC Partners

www.apacpartners.com

 
APAC Partners is a Dyer, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Focused Energy

Focused Energy is a US and German company spun off from the Technical University of Darmstadt in 2021, that will enable safe, clean, and virtually inexhaustible energy production through laser-based nuclear fusion in just a few years. The young company is based in Austin/Texas and Darmstadt/Germany and employs the best minds from relevant research institutes and universities in the USA and in Europe. Focused Energy uses the 30 years of combined experience from its founders in fusion research, coupled with the speed of a young US-German company and private investment, to bring laser-based fusion to market and satisfy the world`s hunger for energy.

Clinsys Clinical Research

Clinsys Clinical Research is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

API WELLNESS CENTER

API WELLNESS CENTER is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soda Health

Soda Health is a healthcare technology company focused on building solutions which eliminate health inequities and create a healthier America. Social Determinants of Health (SDOH) have a major impact on health and wellbeing, as well as the cost of care. Our mission is so important, we found a way to work SDOH into our company name.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.